Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Patterson

Showing results (141-150 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|December 12, 2018
The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against Candida aurisNathan P Wiederhold, Shawn R Lockhart, Laura K Najvar, et al.
Journal of Clinical Microbiology|January 22, 2016
Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal ModelP Lewis White, Nathan P Wiederhold, Juergen Loeffler, et al.
Open Forum Infectious Diseases|July 18, 2025
COVID-19-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients at 7 US Hospitals: Epidemiology and Estimated Likelihood of Invasive Pulmonary Aspergillosis-Results of the Prospective MSG-017 StudyM Hong Nguyen, Sixto M Leal, Luis Ostrosky-Zeichner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcomeThomas F Patterson, Helen W Boucher, Raoul Herbrecht, et al.
Clinical Microbiology Reviews|July 13, 2023
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and ManagementGeorge R Thompson, Jeffrey D Jenks, John W Baddley, et al.
Infection and Immunity|December 30, 2016
The Carbohydrate Lectin Receptor Dectin-1 Mediates the Immune Response to Exserohilum rostratumJennifer L Reedy, Paige E Negoro, Marianela Feliu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyJohan Maertens, Issam Raad, George Petrikkos, et al.
Eukaryotic Cell|July 13, 2006
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatusWilliam J Steinbach, Robert A Cramer, B Zachary Perfect, et al.
Eukaryotic Cell|June 8, 2006
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin productionRobert A Cramer, Michael P Gamcsik, Rhea M Brooking, et al.
Journal of Fungi (Basel, Switzerland)|September 27, 2023
High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against <i>Candida albicans</i> and <i>Candida auris</i> BiofilmsOlabayo H Ajetunmobi, Gina Wall, Bruna Vidal Bonifacio, et al.
Pageof 21

Showing results (141-150 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|December 12, 2018
The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against Candida aurisNathan P Wiederhold, Shawn R Lockhart, Laura K Najvar, et al.
Journal of Clinical Microbiology|January 22, 2016
Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal ModelP Lewis White, Nathan P Wiederhold, Juergen Loeffler, et al.
Open Forum Infectious Diseases|July 18, 2025
COVID-19-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients at 7 US Hospitals: Epidemiology and Estimated Likelihood of Invasive Pulmonary Aspergillosis-Results of the Prospective MSG-017 StudyM Hong Nguyen, Sixto M Leal, Luis Ostrosky-Zeichner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcomeThomas F Patterson, Helen W Boucher, Raoul Herbrecht, et al.
Clinical Microbiology Reviews|July 13, 2023
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and ManagementGeorge R Thompson, Jeffrey D Jenks, John W Baddley, et al.
Infection and Immunity|December 30, 2016
The Carbohydrate Lectin Receptor Dectin-1 Mediates the Immune Response to Exserohilum rostratumJennifer L Reedy, Paige E Negoro, Marianela Feliu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyJohan Maertens, Issam Raad, George Petrikkos, et al.
Eukaryotic Cell|July 13, 2006
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatusWilliam J Steinbach, Robert A Cramer, B Zachary Perfect, et al.
Eukaryotic Cell|June 8, 2006
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin productionRobert A Cramer, Michael P Gamcsik, Rhea M Brooking, et al.
Journal of Fungi (Basel, Switzerland)|September 27, 2023
High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against <i>Candida albicans</i> and <i>Candida auris</i> BiofilmsOlabayo H Ajetunmobi, Gina Wall, Bruna Vidal Bonifacio, et al.
Pageof 21